{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:26:14Z","timestamp":1786983974994,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"NRF","doi-asserted-by":"publisher","award":["2019M3E5D1A02068082"],"award-info":[{"award-number":["2019M3E5D1A02068082"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.actbio.2020.09.014","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T02:45:57Z","timestamp":1599792357000},"page":"356-367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["A bilirubin-conjugated chitosan nanotheranostics system as a platform for reactive oxygen species stimuli-responsive hepatic fibrosis therapy"],"prefix":"10.1016","volume":"116","author":[{"given":"Suchithra Poilil","family":"Surendran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reju George","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myeong Ju","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hyuk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Yeon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.actbio.2020.09.014_bib0001","doi-asserted-by":"crossref","unstructured":"R. G. Wells, \u201cHepatic Fibrosis in Children and Adults,\u201d vol. 9, no. 4, pp. 99\u2013101, 2017.","DOI":"10.1002\/cld.623"},{"issue":"4","key":"10.1016\/j.actbio.2020.09.014_bib0002","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.cld.2008.07.008","article-title":"Cellular sources of extracellular matrix in hepatic fibrosis","volume":"12","author":"Wells","year":"2008","journal-title":"Clin. Liver Dis."},{"issue":"7","key":"10.1016\/j.actbio.2020.09.014_bib0003","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.bbadis.2012.11.002","article-title":"Extracellular matrix degradation in liver fibrosis: biochemistry and regulation","volume":"1832","author":"Iredale","year":"2013","journal-title":"Biochim. Biophys. Acta \u2013 Mol. Basis Dis."},{"issue":"3","key":"10.1016\/j.actbio.2020.09.014_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0151736","article-title":"Extracellular matrix molecular remodeling in human liver fibrosis evolution","volume":"11","author":"Baiocchini","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.actbio.2020.09.014_bib0005","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4103\/1319-3767.45072","article-title":"Reversal of liver fibrosis","volume":"15","author":"Ismail","year":"2009","journal-title":"Saudi J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.actbio.2020.09.014_bib0006","first-page":"1","article-title":"Liver fibrosis","volume":"411","author":"[Assistant","year":"2008","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.actbio.2020.09.014_bib0007","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s41232-016-0025-2","article-title":"Liver regeneration and fibrosis after inflammation","volume":"36","author":"Tanaka","year":"2016","journal-title":"Inflamm. Regen."},{"issue":"10","key":"10.1016\/j.actbio.2020.09.014_bib0008","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.3748\/wjg.v20.i10.2515","article-title":"Hepatic inflammation and progressive liver fibrosis in chronic liver disease","volume":"20","author":"Czaja","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"7","key":"10.1016\/j.actbio.2020.09.014_bib0009","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1021\/acs.jafc.5b05897","article-title":"Liver fibrosis can be induced by high salt intake through excess reactive oxygen species (ROS) production","volume":"64","author":"Wang","year":"2016","journal-title":"J. Agric. Food Chem."},{"issue":"November 2016","key":"10.1016\/j.actbio.2020.09.014_bib0010","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.redox.2016.12.011","article-title":"Oxidative stress in cancer and fibrosis: opportunity for therapeutic intervention with antioxidant compounds, enzymes, and nanoparticles","volume":"11","author":"Morry","year":"2017","journal-title":"Redox Biol."},{"key":"10.1016\/j.actbio.2020.09.014_bib0011","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.2147\/IJN.S145951","article-title":"Nanoparticles for the treatment of liver fibrosis","volume":"12","author":"Poilil Surendran","year":"2017","journal-title":"Int. J. Nanomed."},{"issue":"5","key":"10.1016\/j.actbio.2020.09.014_bib0012","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1034\/j.1600-0676.2001.210504.x","article-title":"Characteristics of the hepatic stellate cell-selective carrier mannose 6-phosphate modified albumin (M6P28-HSA)","volume":"21","author":"Beljaars","year":"2001","journal-title":"Liver"},{"issue":"5","key":"10.1016\/j.actbio.2020.09.014_bib0013","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1258\/ebm.2011.010375","article-title":"The role of the renin-angiotensin system in liver fibrosis","volume":"236","author":"Munshi","year":"2011","journal-title":"Exp. Biol. Med."},{"issue":"2","key":"10.1016\/j.actbio.2020.09.014_bib0014","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/hep.510290203","article-title":"Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis","volume":"29","author":"Schneider","year":"1999","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.actbio.2020.09.014_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0145512","article-title":"Effectiveness of losartan-loaded hyaluronic acid (HA) micelles for the reduction of advanced hepatic fibrosis in C3H\/HeN mice model","volume":"10","author":"Thomas","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.actbio.2020.09.014_bib0016","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1478-3231.2011.02493.x","article-title":"Role of angiotensin-1 receptor blockade in cirrhotic liver resection","volume":"31","author":"Bahde","year":"2011","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.actbio.2020.09.014_bib0017","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/hep.23419","article-title":"Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats","volume":"51","author":"Moreno","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.actbio.2020.09.014_bib0018","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/adhm.201200423","article-title":"Current progress in reactive oxygen species (ROS)-Responsive materials for biomedical applications","volume":"2","author":"Lee","year":"2013","journal-title":"Adv. Healthc. Mater."},{"issue":"1","key":"10.1016\/j.actbio.2020.09.014_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/advs.201600124","article-title":"Reactive-oxygen-species-responsive drug delivery systems: promises and challenges","volume":"4","author":"Saravanakumar","year":"2017","journal-title":"Adv. Sci."},{"issue":"3","key":"10.1016\/j.actbio.2020.09.014_bib0020","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/btm2.10014","article-title":"ROS-responsive drug delivery systems","volume":"1","author":"Liang","year":"2016","journal-title":"Bioeng. Transl. Med."},{"issue":"2","key":"10.1016\/j.actbio.2020.09.014_bib0021","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1021\/nn4058787","article-title":"Nanoparticles with dual responses to oxidative stress and reduced pH for drug release and anti-inflammatory applications","volume":"8","author":"Pu","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2020.09.014_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep29240","article-title":"Bilirubin is an endogenous antioxidant in human vascular endothelial cells","volume":"6","author":"Ziberna","year":"2016","journal-title":"Sci. Rep."},{"issue":"13","key":"10.1016\/j.actbio.2020.09.014_bib0023","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1073\/pnas.0813132106","article-title":"Bilirubin and glutathione have complementary antioxidant and cytoprotective roles","volume":"106","author":"Sedlak","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.actbio.2020.09.014_bib0024","first-page":"1","article-title":"Antioxidant bilirubin works in multiple ways to reduce risk for obesity and its health complications","volume":"5","author":"DInicolantonio","year":"2018","journal-title":"Open Hear."},{"issue":"36","key":"10.1016\/j.actbio.2020.09.014_bib0025","doi-asserted-by":"crossref","first-page":"10676","DOI":"10.1002\/anie.201604858","article-title":"Multistimuli-responsive bilirubin nanoparticles for anticancer therapy","volume":"55","author":"Lee","year":"2016","journal-title":"Angew. Chem. \u2013 Int. Ed."},{"issue":"17","key":"10.1016\/j.actbio.2020.09.014_bib0026","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1016\/j.biomaterials.2010.02.042","article-title":"Glycyrrhetinic acid-modified chitosan\/poly(ethylene glycol) nanoparticles for liver-targeted delivery","volume":"31","author":"Tian","year":"2010","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.actbio.2020.09.014_bib0027","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jconrel.2008.07.029","article-title":"Galactosylated poly(ethylene glycol)-chitosan-graft-polyethylenimine as a gene carrier for hepatocyte-targeting","volume":"131","author":"Jiang","year":"2008","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.actbio.2020.09.014_bib0028","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.actbio.2010.11.042","article-title":"Fabrication of lactobionic-loaded chitosan microcapsules as potential drug carriers targeting the liver","volume":"7","author":"Zhang","year":"2011","journal-title":"Acta Biomater."},{"issue":"1\u20132","key":"10.1016\/j.actbio.2020.09.014_bib0029","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijpharm.2008.03.039","article-title":"Glycyrrhizin surface-modified chitosan nanoparticles for hepatocyte-targeted delivery","volume":"359","author":"Lina","year":"2008","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.actbio.2020.09.014_bib0030","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1039\/c3nr00338h","article-title":"Advances in chitosan-based drug delivery vehicles","volume":"5","author":"Hu","year":"2013","journal-title":"Nanoscale"},{"key":"10.1016\/j.actbio.2020.09.014_bib0031","first-page":"765","article-title":"Recent advances of chitosan nanoparticles as drug carriers","volume":"6","author":"Wang","year":"2011","journal-title":"Int. J. Nanomedicine"},{"issue":"3","key":"10.1016\/j.actbio.2020.09.014_bib0032","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.actbio.2009.08.027","article-title":"Controlled and extended drug release behavior of chitosan-based nanoparticle carrier","volume":"6","author":"Yuan","year":"2010","journal-title":"Acta Biomater."},{"issue":"1","key":"10.1016\/j.actbio.2020.09.014_bib0033","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2009.09.004","article-title":"Biodegradation, biodistribution and toxicity of chitosan","volume":"62","author":"Kean","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.actbio.2020.09.014_bib0034","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ijpharm.2011.09.006","article-title":"Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery","volume":"421","author":"Liu","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"6","key":"10.1016\/j.actbio.2020.09.014_bib0035","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0731-7085(03)00155-9","article-title":"A validated1H NMR method for the determination of the degree of deacetylation of chitosan","volume":"32","author":"Lavertu","year":"2003","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"9","key":"10.1016\/j.actbio.2020.09.014_bib0036","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.bbabio.2007.06.004","article-title":"Infrared spectroscopy of proteins","volume":"1767","author":"Barth","year":"2007","journal-title":"Biochim. Biophys. Acta \u2013 Bioenergy"},{"issue":"3","key":"10.1016\/j.actbio.2020.09.014_bib0037","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4236\/ojapps.2014.43012","article-title":"Vibrational studies of different human body disorders using FTIR spectroscopy","volume":"4","author":"Kumar","year":"2014","journal-title":"Open J. Appl. Sci."},{"issue":"1","key":"10.1016\/j.actbio.2020.09.014_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/advs.201901992","article-title":"A tailored multifunctional anticancer nanodelivery system for ruthenium-based photosensitizers: tumor microenvironment adaption and remodeling","volume":"7","author":"Liang","year":"2020","journal-title":"Adv. Sci."},{"issue":"11","key":"10.1016\/j.actbio.2020.09.014_bib0039","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/labinvest.2008.91","article-title":"Activation of hepatic stellate cells is associated with cytokine expression in thioacetamide-induced hepatic fibrosis in mice","volume":"88","author":"Palacios1","year":"2008","journal-title":"Lab. Investig."},{"key":"10.1016\/j.actbio.2020.09.014_bib0040","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.biomaterials.2017.06.014","article-title":"Bilirubin nanoparticles ameliorate allergic lung inflammation in a mouse model of asthma","volume":"140","author":"Kim","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2020.09.014_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/151683","article-title":"Amphiphiles self-assembly: Basic concepts and future perspectives of supramolecular approaches","volume":"2015","author":"Lombardo","year":"2015","journal-title":"Adv. Condens. Matter Phys."},{"issue":"August","key":"10.1016\/j.actbio.2020.09.014_bib0042","first-page":"1","article-title":"Development and characterization of lecithin-based self-assembling mixed polymeric micellar (saMPMs) drug delivery systems for curcumin","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.actbio.2020.09.014_bib0043","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/BF02977807","article-title":"Development of new reverse micellar microencapsulation technique to load water-soluble drug into PLGA microspheres","volume":"28","author":"Kim","year":"2005","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.actbio.2020.09.014_bib0044","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.biomaterials.2017.04.029","article-title":"PEGylated bilirubin nanoparticle as an anti-oxidative and anti-inflammatory demulcent in pancreatic islet xenotransplantation","volume":"133","author":"Kim","year":"2017","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.actbio.2020.09.014_bib0045","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/sj.bjp.0705339","article-title":"An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells","volume":"139","author":"Kurikawa","year":"2003","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.actbio.2020.09.014_bib0046","first-page":"33","article-title":"The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases","volume":"38","author":"Hazel Mae","year":"2016","journal-title":"Drug Saf."},{"issue":"9","key":"10.1016\/j.actbio.2020.09.014_bib0047","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.actbio.2020.09.014_bib0048","doi-asserted-by":"crossref","first-page":"6035","DOI":"10.2147\/IJN.S208496","article-title":"Co-disposition of chitosan nanoparticles by multi types of hepatic cells and their subsequent biological elimination: the mechanism and kinetic studies at the cellular and animal levels","volume":"14","author":"Jiang","year":"2019","journal-title":"Int. J. Nanomed."},{"issue":"4","key":"10.1016\/j.actbio.2020.09.014_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0175717","article-title":"A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis","volume":"12","author":"McPherson","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.actbio.2020.09.014_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/302602","article-title":"Erratum: effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease: Fatty liver protection trial by telmisartan or losartan study (FANTASY) (International Journal of Endocrinology)","volume":"2014","author":"Hirata","year":"2014","journal-title":"Int. J. Endocrinol."},{"issue":"3","key":"10.1016\/j.actbio.2020.09.014_bib0051","doi-asserted-by":"crossref","first-page":"249","DOI":"10.21037\/hbsn.2016.02.06","article-title":"Losartan may inhibit the progression of liver fibrosis in chronic HCV patients","volume":"5","author":"Salama","year":"2016","journal-title":"HepatoBiliary Surg. Nutr."},{"issue":"48","key":"10.1016\/j.actbio.2020.09.014_bib0052","doi-asserted-by":"crossref","first-page":"7560","DOI":"10.3748\/wjg.v11.i48.7560","article-title":"Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study","volume":"11","author":"Sookoian","year":"2005","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.actbio.2020.09.014_bib0053","first-page":"540","article-title":"Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl4","volume":"6","author":"Wei","year":"2000","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.actbio.2020.09.014_bib0054","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.semperi.2011.02.005","article-title":"Bilirubin production and the risk of bilirubin neurotoxicity","volume":"35","author":"Stevenson","year":"2011","journal-title":"Semin. Perinatol."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706120305286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706120305286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:30:47Z","timestamp":1761672647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706120305286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":54,"alternative-id":["S1742706120305286"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2020.09.014","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A bilirubin-conjugated chitosan nanotheranostics system as a platform for reactive oxygen species stimuli-responsive hepatic fibrosis therapy","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2020.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd on behalf of Acta Materialia Inc.","name":"copyright","label":"Copyright"}]}}